Plain-English translation of NCT07306559 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is the first human trial of , a new medication designed to help your immune system fight cancer. The study is testing whether this treatment is safe to use and whether it can shrink tumors in people with advanced germ cell, endometrial, or ovarian cancers that have stopped responding to standard therapies. Researchers will gradually increase the dose to find the highest amount the medication that people can tolerate while potentially benefiting from treatment.
For people with these advanced cancers that no longer respond to conventional treatment, there are often limited options left. This medication works by activating the immune system in a new way, and this trial is needed to determine if it is safe enough and effective enough to help patients like you.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as an injection once a week for 6 weeks (2 cycles of 3 weeks each), then every 3 weeks after that. You'll visit the study site regularly for check-ups, blood tests, and tumor imaging, and some visits may require overnight stays. If the treatment is helping you, you can continue in the study for up to 3 years, with doctors monitoring your health and any side effects throughout.
AI-generated summary from trial data · Sep 2, 2026 · Not medical advice
United States
Belgium